Overview

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Status:
Completed
Trial end date:
2019-03-27
Target enrollment:
Participant gender:
Summary
Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer